» Articles » PMID: 9746596

Intestinal Secretory Factor Released by Macrophages Stimulated with Clostridium Difficile Toxin A: Role of Interleukin 1beta

Overview
Journal Infect Immun
Date 1998 Sep 24
PMID 9746596
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridium difficile toxin A is associated with enterocolitis in animals and humans. However, the mechanisms of its secretory and damaging effects are not totally understood. In this work, we examined the intestinal secretion of electrolytes and water caused by supernatants from macrophages stimulated with toxin A in rabbit ileal mucosa mounted in Ussing chambers. We also investigated the mechanism by which the intestinal secretory factor (ISF) is released from stimulated macrophages. Supernatants from macrophages stimulated with toxin A caused potent intestinal secretion (change in short-circuit current [DeltaIsc], 76 microA x cm-2; P < 0.01). The release of the ISF was pertussis toxin sensitive (reduction, 61%; P < 0.01) and was also reduced (P < 0.05) by a protein synthesis inhibitor (67%), protease inhibitors (57%), a phospholipase A2 inhibitor (54%), a cyclo-oxygenase inhibitor (62%), a dual cyclo- and lipoxygenase inhibitor (48%), a platelet-activating factor (PAF) receptor antagonist (55%), and tumor necrosis factor alpha (TNF-alpha) synthesis inhibitors (48%). However, this release was not inhibited by a lipo-oxygenase inhibitor. Monoclonal anti-interleukin 1beta (IL-1beta) but not anti-IL-1alpha antibody blocked (72%; P < 0.01) the secretory action of the ISF, as did recombinant human IL-1 receptor antagonist (80%; P < 0.01). High levels of IL-1beta (3,476 pg/ml) were detected by an enzyme-linked immunosorbent assay in the above supernatants. Furthermore, the addition of IL-1beta to the serosal side caused a potent secretory effect (DeltaIsc, 80 microA x cm-2; P < 0.01). These results show that macrophages stimulated with toxin A release an ISF capable of provoking intestinal secretion. The regulation of this factor is dependent upon the activation of the G protein. In addition, prostaglandins, PAF, and TNF-alpha are involved in the release of the ISF. We conclude that IL-1beta is probably the ISF released by macrophages in response to toxin A.

Citing Articles

The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Sun X, Hirota S Mol Immunol. 2014; 63(2):193-202.

PMID: 25242213 PMC: 4254213. DOI: 10.1016/j.molimm.2014.09.005.


Clostridium difficile toxin B differentially affects GPCR-stimulated Ca2+ responses in macrophages: independent roles for Rho and PLA2.

Rebres R, Moon C, Decamp D, Lin K, Fraser I, Milne S J Leukoc Biol. 2010; 87(6):1041-57.

PMID: 20200401 PMC: 2872536. DOI: 10.1189/jlb.1108708.


Clostridium difficile toxins: mechanism of action and role in disease.

Voth D, Ballard J Clin Microbiol Rev. 2005; 18(2):247-63.

PMID: 15831824 PMC: 1082799. DOI: 10.1128/CMR.18.2.247-263.2005.


Recent emergence of an epidemic clindamycin-resistant clone of Clostridium difficile among Polish patients with C. difficile-associated diarrhea.

Pituch H, van Belkum A, van den Braak N, Obuch-Woszczatynski P, Verbrugh H, Meisel-Mikolajczyk F J Clin Microbiol. 2003; 41(9):4184-7.

PMID: 12958245 PMC: 193821. DOI: 10.1128/JCM.41.9.4184-4187.2003.

References
1.
Smith P, Chiossone D, McCafferty G . Characterization of LTC4 effects on rabbit ileal mucosa in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1990; 341(1-2):94-100. DOI: 10.1007/BF00195064. View

2.
Dinarello C, Thompson R . Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today. 1991; 12(11):404-10. DOI: 10.1016/0167-5699(91)90142-G. View

3.
Moreira A, Sampaio E, Zmuidzinas A, Frindt P, Smith K, Kaplan G . Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993; 177(6):1675-80. PMC: 2191046. DOI: 10.1084/jem.177.6.1675. View

4.
Bussolino F, Camussi G, Baglioni C . Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem. 1988; 263(24):11856-61. View

5.
Marshall J, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M . Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest. 1996; 97(4):1122-8. PMC: 507161. DOI: 10.1172/JCI118506. View